At Last, AZ’s Imfinzi/Tremelimumab Cancer Combo Shows Survival Benefit
Could Signal First Tremelimumab Approval
After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.
You may also be interested in...
AstraZeneca Confident About Evusheld's Future Growth
Now approved for the treatment as well as the prevention of COVID-19 in the EU and Japan, the UK major’s antibody combo passed the $500m sales barrier in the third quarter and CEO Pascal Soriot is confident that growth will continue.
AstraZeneca CTLA-4 Inhibitor Imjudo (Finally) Wins FDA Approval
More than a decade after Pfizer gave up on it, tremelimumab won approval combined with PD-L1 inhibitor Imfinzi for frontline hepatocellular carcinoma, ahead of Bristol’s Yervoy/Opdivo second-line indication.
AstraZeneca’s Imfinzi/Treme Combo Fails To Match Leaders In First-Line Lung Cancer
The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.